| Previous Close | 54.14 |
| Open | 54.19 |
| Bid | 54.29 x 200 |
| Ask | 55.00 x 300 |
| Day's Range | 53.76 - 54.73 |
| 52 Week Range | 42.58 - 75.36 |
| Volume | 1,701,639 |
| Avg. Volume | 1,069,220 |
| Market Cap | 7.76B |
| Beta | 2.57 |
| PE Ratio (TTM) | -42.83 |
| EPS (TTM) | -1.27 |
| Earnings Date | Jul 27, 2017 |
| Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 58.20 |
- Zacks•8 days ago
The Zacks Analyst Blog Highlights: Merck, Celgene, Gilead Sciences, Seattle Genetics and Vanda Pharmaceuticals
The Zacks Analyst Blog Highlights: Merck, Celgene, Gilead Sciences, Seattle Genetics and Vanda Pharmaceuticals
Zacks•8 days ago5 Drug Stocks Well Poised to Beat Q2 Earnings Estimates
The NYSE ARCA Pharmaceutical Index has risen almost 9.8% year to date.
- Business Wire•16 days ago
Seattle Genetics to Host Conference Call and Webcast Discussion of Second Quarter Financial Results on July 27, 2017
Seattle Genetics, Inc. announced today that it will report its second quarter financial results on Thursday, July 27, 2017 after the close of financial markets. Following the results announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update.
